News

Labopharm has commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products against Par Pharmaceutical, relating to Ultram ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are

GlaxoSmithKline (GSK) has signed a partnership with Oswaldo Cruz Foundation (Fiocruz) to develop and manufacture vaccines for pressing public health priorities in Brazil. The agreement will establish a

Epeius’ Rexin-G, has been granted Fast Track designation by the FDA for use as a second-line treatment for advanced or metastatic pancreatic cancer. The Fast Track Product designation

A new consortium has been formed to boost drug development for the treatment of two diseases, African sleeping sickness and leishmaniasis. Reportedly, the new consortium will target parasite-specific

University of Texas in Houston, in a study, has reported that stereotactic body radiotherapy (SBRT) is a highly effective alternative treatment for some cancer patients with spinal metastases.

SynCo Bio Partners (SynCo) has entered into a strategic partnership with Versartis to produce Versartis’ lead drug candidate – VRS-859. Under the agreement, SynCo will further develop the

Cellceutix has signed an agreement with Girindus America for the manufacture of Kevetrin active pharmaceutical ingredient. Terms of the agreement were not disclosed. Kevetrin is being developed to

AlphaRx has completed the lyophilization process for Zysolin, allowing the company to proceed to clinical batch material manufacturing for human trials. The company said that the process has

Ore Pharmaceuticals has reported a net loss of $2.5m, or $0.47 per share for the second quarter of 2009, a decrease when compared to a net loss of